DOCSLIB.ORG

HS Number HS Description SITC3 SIC 101110000 Horses, Live, Purebred

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HS Number HS Description SITC3 SIC 101110000 Horses, Live, Purebred HS Number HS Description SITC3 SIC 101110000 Horses, live, purebred breeding SITC-00151 SIC-0272 101190000 Horses, live, except purebred breeding animals SITC-00151 SIC-0272 101200000 Asses, mules and hinnies, live SITC-00152 SIC-0272 102100010 Bovine animals, live, purebred breeding dairy male SITC-00111 SIC-0241 102100020 Bovine animals live, purebred breedng dairy female SITC-00111 SIC-0241 102100030 Bovine animls, purebred breeding except dairy male SITC-00111 SIC-0211 102100050 Bovine anmls purebred breeding except dairy female SITC-00111 SIC-0211 102900000 Bovine animals, live, nesoi SITC-00119 SIC-0211 103100000 Swine, live, purebred breeding animals SITC-00131 SIC-0213 103910000 Swine, live, nesoi, weighing less than 50 kg each SITC-00139 SIC-0213 103920000 Swine, live, nesoi, weighing 50 kg or more each SITC-00139 SIC-0213 104100000 Sheep, live SITC-00121 SIC-0214 104200000 Goats, live SITC-00122 SIC-0214 105110010 Chickens live, not ov 185g breeding stock,egg-type SITC-00141 SIC-0259 105110020 Chickens live not ov 185g breeding stock,meat-type SITC-00141 SIC-0259 105110040 Chickens, live, nov 185g ea, ex breeding stock SITC-00141 SIC-0259 105120000 Turkeys, live, weighing not over 185 g each SITC-00141 SIC-0259 105190000 Other live poultry not weighing not over 185 g ea. SITC-00141 SIC-0259 105920000 Chickens, weighing not over 2,000 g each SITC-00149 SIC-0259 105930000 Chickens, weighing more than 2,000 g each SITC-00149 SIC-0259 105990000 Turkeys, ducks, geese, guineas, live, over 185g ea SITC-00149 SIC-0259 106005070 Rabbits and hares, live SITC-00190 SIC-0271 106005090 Animals, live, nesoi SITC-00190 SIC-0279 201100010 Carcasses/half-carcasses of veal, fresh or chilled SITC-01111 SIC-2011 201100090 Carcasses/half-carcasses bovine anmls nesoi fr/chl SITC-01111 SIC-2011 201203550 Meat bovine anmls nesoi cuts w/bone procsd frh/chd SITC-01111 SIC-2011 201206000 Meat bovine anmls cuts w/bone ex procssd frsh/chld SITC-01111 SIC-2011 201303550 Meat bovine anmls boneless processed fresh/chilled SITC-01112 SIC-2011 201306000 Meat bovine anmls, boneless ex processd, frsh/chld SITC-01112 SIC-2011 202100010 Carcasses and half-carcasses of veal, frozen SITC-01121 SIC-2011 202100090 Carcasses/half-carcasses bovine anmls nesoi frozen SITC-01121 SIC-2011 202203550 Meat bovine anmls nesoi cuts w/bone procssd frozen SITC-01121 SIC-2011 202206000 Meat bovine anmls cuts w/bone ex processed, frozen SITC-01121 SIC-2011 202303550 Meat bovine animals boneless, processed, frozen SITC-01122 SIC-2011 202306000 Meat bovine animals boneless except processed frzn SITC-01122 SIC-2011 203110000 Carcasses & half-carcasses of swine fresh, chilled SITC-01221 SIC-2011 203121000 Hams/shoulders & cuts, bone in processed frsh/chld SITC-01221 SIC-2011 203129000 Hams/shoulders & cuts, bone in ex processed fr, ch SITC-01221 SIC-2011 203192000 Meat of swine, nesoi, processed, fresh or chilled SITC-01221 SIC-2011 203194000 Meat of swine, nesoi, ex processed, fresh/chilled SITC-01221 SIC-2011 203210000 Carcasses and half-carcasses of swine, frozen SITC-01222 SIC-2011 203221000 Hams, shoulders & cuts, bone in, processed, frozen SITC-01222 SIC-2011 203229000 Hams/shoulders & cuts, bone in ex processed, frozn SITC-01222 SIC-2011 203292000 Meat of swine, nesoi, processed, frozen SITC-01222 SIC-2011 203294000 Meat of swine, nesoi, except processed, frozen SITC-01222 SIC-2011 204100000 Carcasses and half-carcasses of lamb fresh/chilled SITC-01211 SIC-2011 204210000 Carcasses & half-carcasses of sheep, fresh/chilled SITC-01211 SIC-2011 204220000 Meat of sheep, cuts, bone in nesoi, fresh, chilled SITC-01211 SIC-2011 204230000 Meat of sheep, boneless, fresh or chilled SITC-01211 SIC-2011 204300000 Carcasses and half-carcasses of lamb, frozen SITC-01212 SIC-2011 204410000 Carcasses and half-carcasses of sheep, frozen SITC-01212 SIC-2011 204420000 Meat of sheep, cuts with bone in, nesoi, frozen SITC-01212 SIC-2011 204430000 Meat of sheep, boneless, frozen SITC-01212 SIC-2011 204500000 Meat of goats, fresh, chilled or frozen SITC-01213 SIC-2011 205000000 Meat of horses, asses, mules, hinnies fr, chld, fz SITC-01240 SIC-2011 206100000 Offal of bovine animals, edible, fresh or chilled SITC-01251 SIC-2011 206210000 Tongues of bovine animals, edible, frozen SITC-01252 SIC-2011 206220000 Livers of bovine animals, edible, frozen SITC-01252 SIC-2011 206290000 Offal of bovine animals, edible, nesoi, frozen SITC-01252 SIC-2011 206300000 Offal of swine, edible, fresh or chilled SITC-01253 SIC-2011 206410000 Livers of swine, edible, frozen SITC-01254 SIC-2011 206490000 Offal of swine except livers, edible, frozen SITC-01254 SIC-2011 206800000 Offal sheep,goat,horse,ass,mule/hinny edible fr/ch SITC-01255 SIC-2011 206900020 Offal of sheep (including lamb), edible, frozen SITC-01256 SIC-2011 206900040 Offal, goat, horse, asses, mule, hinnies edible fr SITC-01256 SIC-2011 207110020 Chickens, young, not cut in pieces, fresh, chilled SITC-01231 SIC-2015 207110040 Chickens, nesoi, not cut in pieces, fresh, chilled SITC-01231 SIC-2015 207120020 Chickens, young, not cut in pieces, frozen SITC-01232 SIC-2015 207120040 Chickens, nesoi, not cut in pieces, frozen SITC-01232 SIC-2015 207130000 Chicken cuts & edible offal (incl liver) frsh/chld SITC-01234 SIC-2015 207140000 Chicken cuts and edible offal (inc livers), frozen SITC-01235 SIC-2015 207240000 Turkeys, not cut in pieces, fresh or chilled SITC-01231 SIC-2015 207250000 Turkeys, not cut in pieces, frozen SITC-01232 SIC-2015 207260000 Turkey cuts & edible offal (incl liver) frsh/chlld SITC-01234 SIC-2015 207270000 Turkey cuts and edible offal (includ liver) frozen SITC-01235 SIC-2015 207320000 Ducks, geese and guineas, whole, fresh or chilled SITC-01231 SIC-2015 207330000 Ducks, geese & guineas, not cut in pieces, frozen SITC-01232 SIC-2015 207340000 Livers fatty of geese/ducks/guinea edible frsh/chd SITC-01233 SIC-2015 207350000 Ducks/geese/guineas cuts & offal ex liver frsh/chd SITC-01234 SIC-2015 207360000 Duck, geese, guinea cuts/edible offal (in livr) fz SITC-01235 SIC-2015 208100000 Rabbit or hare meat & offal fresh, chilled, frozen SITC-01291 SIC-2015 208200000 Frogs' legs, fresh, chilled or frozen SITC-01292 SIC-2015 208900000 Meat & edible meat offal nesoi, fresh, chld, frozn SITC-01299 SIC-2015 209000000 Pig & poultry fat frsh chld frzn salted dried smkd SITC-41131 SIC-2011 210110000 Hams, shoulders & cuts, bone in, salted, drd, smkd SITC-01611 SIC-2011 210120020 Bacon SITC-01612 SIC-2011 210120040 Bellies, cuts, swine, saltd, in brine, dried, smkd SITC-01612 SIC-2011 210190000 Meat of swine nesoi, salted, in brine, dried, smkd SITC-01619 SIC-2011 210200000 Meat, bovine animals, salted, in brine, drd, smokd SITC-01681 SIC-2011 210900000 Meat & offal, salted, drd, smkd, incl flour & meal SITC-01689 SIC-2011 301100000 Fish, ornamental, live SITC-03411 SIC-0273 301910000 Trout (salmo trutta,oncorhynchus mykiss, etc) live SITC-03411 SIC-0273 301920000 Eels (anguilla spp.), live SITC-03411 SIC-0273 301930000 Carp, live SITC-03411 SIC-0273 301990000 Fish, live, nesoi SITC-03411 SIC-0273 302110010 Rainbow trout farmed fresh/chilled exc flt/lvr/roe SITC-03412 SIC-0273 302110090 Trout (except farmed rainbow trout) fresh/chilled SITC-03412 SIC-0912 302120003 Atlantic salmon farmed,fresh/chilld ex flt/lvr/roe SITC-03412 SIC-0273 302120004 Atlantic salmon nt farmd frsh/chlld ex flt/lvr/roe SITC-03412 SIC-0912 302120012 Chinook (king) salmon frsh/chill ex fillet/lvr/roe SITC-03412 SIC-0912 302120022 Chum (dog) salmon fresh/chilld ex fillet/liver/roe SITC-03412 SIC-0912 302120032 Pink (humpie) salmon frsh/chilld ex fillet/lvr/roe SITC-03412 SIC-0912 302120042 Sockeye (red) salmon frsh/chilld ex fillet/lvr/roe SITC-03412 SIC-0912 302120052 Coho (silver) salmon frsh/chilld ex fillet/lvr/roe SITC-03412 SIC-0912 302120062 Salmon, nesoi, fresh or chilled ex fillet/lvr/roe SITC-03412 SIC-0912 302190000 Salmonidae, nesoi, fresh or chilled SITC-03412 SIC-0912 302210000 Halibut/greenland turbot ex fillet, lvr, roe fr/ch SITC-03413 SIC-0912 302220000 Plaice except fillets, livers, roes, fresh/chilled SITC-03413 SIC-0912 302230000 Sole except fillets, livers & roes, fresh, chilled SITC-03413 SIC-0912 302290000 Flatfish nesoi except fillet, liver roe fresh/chld SITC-03413 SIC-0912 302310000 Albacore/longfinned tunas ex fillet lvr roe, fr/ch SITC-03414 SIC-0912 302320000 Yellowfin tunas except fillets, livers, roes fr/ch SITC-03414 SIC-0912 302330000 Skipjack tunas except fillets, liver, roe, fr, ch SITC-03414 SIC-0912 302390020 Bluefin tunas except fillets, liver, roe, frsh, ch SITC-03414 SIC-0912 302390040 Tunas nesoi except fillets, livers, roes, fr, chld SITC-03414 SIC-0912 302400000 Herrings except fillets, livers, roes, fresh, chld SITC-03415 SIC-0912 302500000 Cod except fillets, livers & roes, fresh, chilled SITC-03416 SIC-0912 302610000 Sardines except fillet, liver, roe, fresh, chilled SITC-03415 SIC-0912 302620000 Haddock except fillets, liver, roe, fresh, chilled SITC-03418 SIC-0912 302630000 Atlantic pollock except fillet, liver, roe, fr, ch SITC-03418 SIC-0912 302640000 Mackerel except fillet, liver, roe, fresh, chilled SITC-03417 SIC-0912 302650010 Dogfish (squalus spp.) ex fillet/liver/roe frsh/ch SITC-03418 SIC-0912 302650090 Other shark, excpt fillets, livers and roes, fr/ch SITC-03418 SIC-0912 302660000 Eels except fillets, livers & roes, fresh, chilled SITC-03418 SIC-0912 302693010 Sablefish frsh/chilld except fillets, livers, roes SITC-03418 SIC-0912 302693020 Lincod(ophiodon elongatus) fresh/chilld ex flt/roe SITC-03418 SIC-0912
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub
    US 20110263526A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub. Date: Oct. 27, 2011 (54) NITRICOXIDE RELEASING PRODRUGS OF CD7C 69/96 (2006.01) THERAPEUTICAGENTS C07C 319/22 (2006.01) CD7C 68/02 (2006.01) (75) Inventor: Apparao SATYAM, Mumbai (IN) A6IP 29/00 (2006.01) A6IP 9/00 (2006.01) (73) Assignee: PIRAMAL LIFE SCIENCES A6IP37/08 (2006.01) LIMITED, Mumbai (IN) A6IP35/00 (2006.01) A6IP 25/24 2006.O1 (21) Appl. No.: 13/092.245 A6IP 25/08 308: A6IP3L/04 2006.O1 (22) Filed: Apr. 22, 2011 A6IP3L/2 308: Related U.S. Application Data 39t. O 308: (60) Provisional application No. 61/327,175, filed on Apr. A6IP3/10 (2006.01) 23, 2010. A6IPL/04 (2006.01) A6IP39/06 (2006.01) Publication Classification A6IP3/02 (2006.01) (51) Int. Cl. A6IP 9/06 (2006.01) A 6LX 3L/7072 (2006.01) 39t. W 308: A6 IK3I/58 (2006.01) A6IP II/08 (2006.015 A6 IK3I/55 (2006.01) A63/62 (2006.015 A6 IK 3/495 (2006.01) A6 IK 3/4439 (2006.01) (52) U.S. Cl. ........... 514/50: 514/166; 514/172: 514/217; A6 IK 3L/455 (2006.01) 514/255.04: 514/338; 514/356; 514/412; A6 IK 3/403 (2006.01) 514/420; 514/423: 514/510,536/28.53:540/67; A6 IK 3/404 (2006.01) 540/591; 544/396; 546/273.7: 546/318: 548/452: A6 IK 3/40 (2006.01) 548/500: 548/537; 549/464; 558/275 A6 IK3I/265 (2006.01) C7H 9/06 (2006.01) (57) ABSTRACT CO7I 71/00 (2006.01) CO7D 22.3/26 (2006.01) The present invention relates to nitric oxide releasing pro C07D 295/14 (2006.01) drugs of known drugs or therapeutic agents which are repre CO7D 40/12 (2006.01) sented herein as compounds of formula (I) wherein the drugs CO7D 213/80 (2006.01) or therapeutic agents contain one or more functional groups C07D 209/52 (2006.01) independently selected from a carboxylic acid, an amino, a CO7D 209/26 (2006.01) hydroxyl and a sulfhydryl group.
    [Show full text]
  • F1y3x CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1
    )&f1y3X CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1. Except where the context otherwise requires, the headings of this chapter apply only to: (a) Separate chemically defined organic compounds, whether or not containing impurities; (b) Mixtures of two or more isomers of the same organic compound (whether or not containing impurities), except mixtures of acyclic hydrocarbon isomers (other than stereoisomers), whether or not saturated (chapter 27); (c) The products of headings 2936 to 2939 or the sugar ethers and sugar esters, and their salts, of heading 2940, or the products of heading 2941, whether or not chemically defined; (d) Products mentioned in (a), (b) or (c) above dissolved in water; (e) Products mentioned in (a), (b) or (c) above dissolved in other solvents provided that the solution constitutes a normal and necessary method of putting up these products adopted solely for reasons of safety or for transport and that the solvent does not render the product particularly suitable for specific use rather than for general use; (f) The products mentioned in (a), (b), (c), (d) or (e) above with an added stabilizer necessary for their preservation or transport; (g) The products mentioned in (a), (b), (c), (d), (e) or (f) above with an added antidusting agent or a coloring or odoriferous substance added to facilitate their identification or for safety reasons, provided that the additions do not render the product particularly suitable for specific use rather than for general use; (h) The following products, diluted to standard strengths, for the production of azo dyes: diazonium salts, couplers used for these salts and diazotizable amines and their salts.
    [Show full text]
  • Page Numbers in Bold Type Relate to Monograph Titles Index V-A797
    page numbers in bold type relate to monograph titles Index V-A797 Index Page numbers in bold type relate to monograph titles. Pages – Vol I: i – xxxii, (Preliminaries and Introduction) 1 – 1280, (General Notices and Monographs) Pages – Vol II: i – viii, (Preliminaries) 1 – 1220, (General Notices and Monographs) Pages – Vol III: i – viii, (Preliminaries) 1 – 1238, (General Notices and Monographs) Pages – Vol IV: i – viii, (Preliminaries) 1 – 754, (General Notices and Monographs) Pages – Vol V: i – viii, (Preliminaries) 1 – 34, (General Notices) S1 – S144, (Spectra) A1 – A796, (Appendices; Supplementary Chapters) page numbers in bold type relate to monograph titles Index V-A799 Acetate Buffer Solution pH 6.0, see N-Acetyltryptophan see Acetyltryptophan A Acetate Buffer pH 6.0 Acetyltryptophan, I-63 Abacavir, V-S4 Acetate Buffer Solution pH 4.4, V-A152 Acetyltyrosine, I-65 Abacavir Oral Solution, III-85 Acetate Buffer Solution pH 4.5, V-A152 N-Acetyltyrosine see Acetyltyrosine Abacavir Sulfate, I-39 Acetate Buffer Solution pH 4.7, V-A152 Acetyltyrosine Ethyl Ester, V-A21 Abacavir Tablets, III-86 Acetate Buffer Solution pH 5.0, V-A153 Acetyltyrosine Ethyl Ester, 0.2M, V-A21 Abbreviated, V-598 Acetate Buffer Solution pH 6.0, V-A153 Aciclovir, I-67 Adjectives, V-598 Acetate–edetate Buffer Solution pH 5.5, Aciclovir Cream, III-93 Anions, V-598 V-A153 Aciclovir Eye Ointment, III-94 Cations, V-598 Acetates, Reactions of, V-266 Aciclovir Infusion, III-95 Preparations, V-598 Acetazolamide, I-54, V-S5 Aciclovir Intravenous Infusion, see Titles of
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,623,419 B2 Malakhov Et Al
    USOO8623419B2 (12) United States Patent (10) Patent No.: US 8,623,419 B2 Malakhov et al. (45) Date of Patent: Jan. 7, 2014 (54) TECHNOLOGY FOR PREPARATION OF WO 2004/047735 6, 2004 MACROMOLECULAR MICROSPHERES WO WO2005/035088 4/2005 WO 2006/031291 3, 2006 (75) Inventors: Michael P. Malakhov, San Francisco, CA (US); Fang Fang, Rancho Santa Fe, OTHER PUBLICATIONS CA (US) US 5,849,884, 11/09/99, Woiszwillo et al (withdrawn). Agrawal et al., “Basis of rise in intracellular sodium in airway hyper (73) Assignee: Ansun Biopharma, Inc., San Diego, CA responsiveness and asthma.” Lung, 183:375-387. (2005). (US) Alcock, R., et al., “Modifying the release of leuprolide from spray dried OED microparticles,” Journal of Control Release, 82(2-3):429 (*) Notice: Subject to any disclaimer, the term of this 440, (2002). patent is extended or adjusted under 35 Barbey-Morel, C.L., et al., “Role of respiratory tract proteases in U.S.C. 154(b) by 0 days. infectivity of influenza A virus,” Journal of Infectious Diseases, 155:667-672, (1987). (21) Appl. No.: 13/289,644 Bot A.I. et al., “Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract.” Phar (22) Filed: Nov. 4, 2011 maceutical Research, 17(3):275-283, (2000). (65) Prior Publication Data Cryan S.A., "Carrier-based strategies for targeting protein and peptide drugs to the lungs.” American Association of Pharmaceutical US 2012/O116062 A1 May 10, 2012 Scientists PharmSci AAPS electronic resource), 7(1): E20-E41, (2005). Edwards D.A. et al., "Large porous particles for pulmonary drug Related U.S.
    [Show full text]
  • Pharmacology Cito
    Pharmacology Cito 5 Read: it is important! Dear future physicians and pharmaceutists! The scientific and pedagogical staff of the Pharmacology department of the National University of Pharmacy (Kharkiv) presents a new textbook "Pharmacology – Cito!" to you. We want to change the myth that it is impossible to learn pharmacology quickly and qualitatively. The textbook "Pharmacology – Cito!" is published for those, who have decided to connect his or her profession with medicines, but think that a great amount of the information in pharmacology is hard to learn. Taking this fact into account we have decided to help those, who wish to master pharmacology in logical, fast - "Cito!"- version. Not be afraid of pharmacology! The 40-year experience of teaching pharmacology testifies that for the last 10-15 years a tendency of reducing the amount of classroom hours in pharmacology because of increasing the amount of the individual work is being observed. However, because of the lack of time and the constant increasing volume of information in pharmacology, everyone has not enough time to master it soundly and qualitatively. This textbook trains future pharmaceutists and physicians in the pharmacological logic, i.e. knowing the mechanisms of drug action one can understand their pharmacodynamics, naturally, on the basis of pharmacodynamics one can find logically the indications to their application and from their side effects the contraindications can be seen. The information about the peculiarities of medicines has been generalized and given as a pharmacological ―face‖ in tables. The volume of this textbook in pharmacology is sufficient for acquiring the confidence in the opportunity of the further improving of knowledge in this discipline, which is important for a physician and a pharmaceutist.
    [Show full text]
  • Pharmacology
    STATE ESTABLISHMENT «DNIPROPETROVSK MEDICAL ACADEMY OF HEALTH MINISTRY OF UKRAINE» V.I. MAMCHUR, V.I. OPRYSHKO, А.А. NEFEDOV, A.E. LIEVYKH, E.V.KHOMIAK PHARMACOLOGY WORKBOOK FOR PRACTICAL CLASSES FOR FOREIGN STUDENTS STOMATOLOGY DEPARTMENT DNEPROPETROVSK - 2016 2 UDC: 378.180.6:61:615(075.5) Pharmacology. Workbook for practical classes for foreign stomatology students / V.Y. Mamchur, V.I. Opryshko, A.A. Nefedov. - Dnepropetrovsk, 2016. – 186 p. Reviewed by: N.I. Voloshchuk - MD, Professor of Pharmacology "Vinnitsa N.I. Pirogov National Medical University.‖ L.V. Savchenkova – Doctor of Medicine, Professor, Head of the Department of Clinical Pharmacology, State Establishment ―Lugansk state medical university‖ E.A. Podpletnyaya – Doctor of Pharmacy, Professor, Head of the Department of General and Clinical Pharmacy, State Establishment ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ Approved and recommended for publication by the CMC of State Establishment ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ (protocol №3 from 25.12.2012). The educational tutorial contains materials for practical classes and final module control on Pharmacology. The tutorial was prepared to improve self-learning of Pharmacology and optimization of practical classes. It contains questions for self-study for practical classes and final module control, prescription tasks, pharmacological terms that students must know in a particular topic, medical forms of main drugs, multiple choice questions (tests) for self- control, basic and additional references. This tutorial is also a student workbook that provides the entire scope of student’s work during Pharmacology course according to the credit-modular system. The tutorial was drawn up in accordance with the working program on Pharmacology approved by CMC of SE ―Dnipropetrovsk medical academy of Health Ministry of Ukraine‖ on the basis of the standard program on Pharmacology for stomatology students of III - IV levels of accreditation in the specialties Stomatology – 7.110105, Kiev 2011.
    [Show full text]
  • Annex 8 Proposal to Waive in Vivo Bioequivalence Requirements for WHO Model List of Essential Medicines Immediate-Release, Solid Oral Dosage Forms
    © World Health Organization WHO Technical Report Series, No. 937, 2006 Annex 8 Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms Introduction 1. Background 2. WHO revisions to the criteria for Biopharmaceutics Classifi cation System classifi cation 3. WHO extensions to the scope of application of the biowaiver 4. WHO additional criteria for application of the biowaiver procedure 5. Explanation of the tables 6. Biowaiver testing procedure according to WHO Introduction This proposal is closely linked to the Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchange- ability (WHO Technical Report Series, No. 937, Annex 7). It aims to give national authorities suffi cient background information on the various orally administered active pharmaceutical ingredients (APIs) on the WHO Model List of Essential Medicines (EML), also taking into account local usage of the API, to enable them to make an informed decision as to whether generic formulations should be subjected to in vivo bioequivalence (BE) studies or whether a biowaiver can be granted. In light of scientifi c work and dis- cussion in the last decade, some of the criteria used to evaluate the API in terms of potential for a biowaiver have been revised to allow a broadened scope of application. The result is that many APIs on the EML can now be considered for the biowaiver procedure, subject to the usage and risks in the national setting. 1. Background 1.1 Initiatives to allow biowaivers based on the Biopharmaceutics Classifi cation System In 1995 the American Department of Health and Human Services, US Food and Drug Administration (HHS-FDA) instigated the Biopharmaceutics 391 TSR2006_Annexs6-9.indd 391 4.5.2006 15:48:56 Classifi cation System (BCS), with the aim of granting so-called biowaiv- ers for scale-up and post-approval changes (SUPAC) (www.fda.gov/cder/ guidance/cmc5.pdf).
    [Show full text]
  • Page Numbers in Bold Type Relate to Monograph Titles Index A769
    page numbers in bold type relate to monograph titles Index A769 Index Page numbers in bold type relate to monograph titles. Pages – Vol I: i – xxviii, (Preliminaries and Introduction) 1 – 1172, (General Notices and Monographs) Pages – Vol II: xxix – xxxvi, (Preliminaries) 1173 – 2252, (General Notices and Monographs) Pages – Vol III: xxxvii – xliv, (Preliminaries) 2253 – 3794, (General Notices and Monographs) Pages – Vol IV: xlv – lii, (Preliminaries) 3795 – 3828, (General Notices) S1 – S134, (Spectra) A1 – A768, (Appendices; Supplementary Chapters) page numbers in bold type relate to monograph titles Index A771 Acetate–edetate Buffer Solution pH 5.5, Aciclovir Tablets, 2341 A A141 Aciclovir Tablets, Dispersible, 2341 Abbreviated, A519 Acetates, Reactions of, A239 Acicular, A449 Adjectives, A519 Acetazolamide, 52,S5 Acid Blue 92, A19 Anions, A519 Acetazolamide Tablets, 2336 Acid Blue 92 Solution, A19 Cations, A519 Acetic Acid, A17 Acid Blue 83, A19 Preparations, A519 Acetic Acid (6 per cent), 54 Acid Blue 93 Solution, A19 Titles of Monographs, A519 Acetic Acid (33 per cent), 55 Acid Blue 90, A19 Abbreviated Titles, Status of, 7, 1179, Acetic Acid, Anhydrous, A18 Acid Gentian Mixture, 3585 2259, 3801 Acetic Acid, Deuterated, A46 Acid Gentian Oral Solution, 3585 Abnormal Toxicity, Test for, A354 Acetic Acid, Dilute, A18 Acid Potassium Iodobismuthate About, definition of, 5, 1177, 2257, Acetic Acid, Dilute, see Acetic Acid Solution, A100 3799 (6 per cent) Acid Value, A275 Absolute Alcohol, see Ethanol Acetic Acid, Glacial, 54, A18 Acid/base
    [Show full text]
  • Botulinum Toxin
    Botulinum toxin From Wikipedia, the free encyclopedia Jump to: navigation, search Botulinum toxin Clinical data Pregnancy ? cat. Legal status Rx-Only (US) Routes IM (approved),SC, intradermal, into glands Identifiers CAS number 93384-43-1 = ATC code M03AX01 PubChem CID 5485225 DrugBank DB00042 Chemical data Formula C6760H10447N1743O2010S32 Mol. mass 149.322,3223 kDa (what is this?) (verify) Bontoxilysin Identifiers EC number 3.4.24.69 Databases IntEnz IntEnz view BRENDA BRENDA entry ExPASy NiceZyme view KEGG KEGG entry MetaCyc metabolic pathway PRIAM profile PDB structures RCSB PDB PDBe PDBsum Gene Ontology AmiGO / EGO [show]Search Botulinum toxin is a protein and neurotoxin produced by the bacterium Clostridium botulinum. Botulinum toxin can cause botulism, a serious and life-threatening illness in humans and animals.[1][2] When introduced intravenously in monkeys, type A (Botox Cosmetic) of the toxin [citation exhibits an LD50 of 40–56 ng, type C1 around 32 ng, type D 3200 ng, and type E 88 ng needed]; these are some of the most potent neurotoxins known.[3] Popularly known by one of its trade names, Botox, it is used for various cosmetic and medical procedures. Botulinum can be absorbed from eyes, mucous membranes, respiratory tract or non-intact skin.[4] Contents [show] [edit] History Justinus Kerner described botulinum toxin as a "sausage poison" and "fatty poison",[5] because the bacterium that produces the toxin often caused poisoning by growing in improperly handled or prepared meat products. It was Kerner, a physician, who first conceived a possible therapeutic use of botulinum toxin and coined the name botulism (from Latin botulus meaning "sausage").
    [Show full text]
  • SERATEC® Drug Screen
    SERATEC ® Gesellschaft für Biotechnologie mbH Ernst-Ruhstrat-Str. 5 D -37079 Göttingen Phone: +49 (0)551/504 800 • Fax: +49 (0)551/504 80 80 • e-mail: [email protected], web: www.seratec.com SERATEC Drug Screen BZO REF DSC-BZO A visual one-step immunoassay for the qualitative detection of benzodiazepines in human urine. For professional In Vitro diagnostic use only. INTENDED USE A control band with a different antigen/antibody reaction is also added The SERATEC Drug Screen BZO is a lateral flow, one-step immu- to the immunochromatographic membrane strip at the control region noassay for the qualitative detection of benzodiazepines in human (C) to indicate that the test has performed properly. This control line urine at a cut-off of 300 ng/ml (Oxazepam). This product is used to should always appear, regardless of the presence of drug and me- obtain a visual, qualitative result and is intended for professional use. tabolite. This means that negative urine will produce two colored The assay should not be used without proper supervision and is not bands, and positive urine will produce only one band. The presence intended for over the counter sale to lay persons. of this colored band in the control region also serves as 1) verification This assay provides only a preliminary analytical test result. A more that sufficient volume has been added, and 2) that proper flow was specific alternative chemical method must be used in order to obtain obtained. a confirmed analytical result. Gas chromatography/mass spectrome- STORAGE AND STABILITY try (GC/ MS) has been established as the preferred confirmatory The test kit is to be stored refrigerated or at room temperature +4-+30 method by the National Institute of Drug Abuse (NIDA).
    [Show full text]
  • 14 Informe 40.Pdf
    WHO Technical Report Series 937 SPECIFICATIONS This report presents the recommendations of an international WHO EXPERT COMMITTEE group of experts convened by the World Health Organization to consider matters concerning the quality assurance of ON SPECIFICATIONS FOR pharmaceuticals and specifi cations for drug substances and dosage forms. PHARMACEUTICAL PREPARATIONS FOR The report is complemented by a number of annexes. These include: a list of available International Chemical Reference PHARMACEUTICAL Substances and International Infrared Spectra; supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms; updated supplementary guidelines on good manufacturing practices for the manufacture of herbal medicines; supplementary guidelines on Fortieth Report good manufacturing practices for validation; good distribution practices for pharmaceutical products; a model quality assurance PREPARATIONS system for procurement agencies (recommendations for quality assurance systems focusing on prequalifi cation of products and manufacturers, purchasing, storage and distribution of pharmaceutical products); multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability; a proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral WHO dosage forms; and additional guidance for organizations Technical performing in vivo bioequivalence studies.
    [Show full text]